NHS England And Vertex Strike “Lightening Quick” CF Kaftrio/Trikafta Deal
Other Portfolio Style Agreements Could Lead To Quick Access In Other Markets
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
